BACKGROUND: Exhaled nitric oxide (FeNO) is a biomarker of airway inflammation. In the nitric oxide (NO) synthesis pathway, nitric oxide synthases (encoded by NOS1, NOS2A, and NOS3) and arginases (encoded by ARG1 and ARG2) compete for L-arginine. Although FeNO levels are higher in children with asthma/allergy, influence of these conditions on the relationships between variations in these genes and FeNO remains unknown. The aims of the study were to evaluate the role of genetic variations in nitric oxide synthases and arginases on FeNO in children and to assess the influence of asthma and respiratory allergy on these genetic associations. METHODS: Among children (6-11 years) who participated in the southern California Children's Health Study, variations in these five genetic loci were characterized by tagSNPs. FeNO was measured in two consecutive years (N = 2298 and 2515 in Years 1 and 2, respectively). Repeated measures analysis of variance was used to evaluate the associations between these genetic variants and FeNO. RESULTS: Sequence variations in the NOS2A and ARG2 loci were globally associated with FeNO (P = 0.0002 and 0.01, respectively). The ARG2 association was tagged by intronic variant rs3742879 with stronger association with FeNO in asthmatic children (P-interaction = 0.01). The association of a NOS2A promoter haplotype with FeNO varied significantly by rs3742879 genotypes and by asthma. CONCLUSION: Variants in the NO synthesis pathway genes jointly contribute to differences in FeNO concentrations. Some of these genetic influences were stronger in children with asthma. Further studies are required to confirm our findings.
BACKGROUND: Exhaled nitric oxide (FeNO) is a biomarker of airway inflammation. In the nitric oxide (NO) synthesis pathway, nitric oxide synthases (encoded by NOS1, NOS2A, and NOS3) and arginases (encoded by ARG1 and ARG2) compete for L-arginine. Although FeNO levels are higher in children with asthma/allergy, influence of these conditions on the relationships between variations in these genes and FeNO remains unknown. The aims of the study were to evaluate the role of genetic variations in nitric oxide synthases and arginases on FeNO in children and to assess the influence of asthma and respiratory allergy on these genetic associations. METHODS: Among children (6-11 years) who participated in the southern California Children's Health Study, variations in these five genetic loci were characterized by tagSNPs. FeNO was measured in two consecutive years (N = 2298 and 2515 in Years 1 and 2, respectively). Repeated measures analysis of variance was used to evaluate the associations between these genetic variants and FeNO. RESULTS: Sequence variations in the NOS2A and ARG2 loci were globally associated with FeNO (P = 0.0002 and 0.01, respectively). The ARG2 association was tagged by intronic variant rs3742879 with stronger association with FeNO in asthmatic children (P-interaction = 0.01). The association of a NOS2A promoter haplotype with FeNO varied significantly by rs3742879 genotypes and by asthma. CONCLUSION: Variants in the NO synthesis pathway genes jointly contribute to differences in FeNO concentrations. Some of these genetic influences were stronger in children with asthma. Further studies are required to confirm our findings.
Authors: Ting F Leung; Eric K H Liu; Chung Y Li; Iris H S Chan; Edmund Yung; Christopher W K Lam; Gary W K Wong Journal: Pediatr Pulmonol Date: 2006-07
Authors: Karin Storm van's Gravesande; Michael E Wechsler; Hartmut Grasemann; Eric S Silverman; Louis Le; Lyle J Palmer; Jeffrey M Drazen Journal: Am J Respir Crit Care Med Date: 2003-05-08 Impact factor: 21.405
Authors: Corina J Shtir; Paul Marjoram; Stanley Azen; David V Conti; Loic Le Marchand; Christopher A Haiman; Rohit Varma Journal: BMC Genet Date: 2009-11-10 Impact factor: 2.797
Authors: Carrie V Breton; Hyang-Min Byun; Xinhui Wang; Muhammad T Salam; Kim Siegmund; Frank D Gilliland Journal: Am J Respir Crit Care Med Date: 2011-04-21 Impact factor: 21.405
Authors: Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini Journal: Eur J Clin Pharmacol Date: 2021-01-07 Impact factor: 2.953
Authors: Muhammad T Salam; Hyang-Min Byun; Fred Lurmann; Carrie V Breton; Xinhui Wang; Sandrah P Eckel; Frank D Gilliland Journal: J Allergy Clin Immunol Date: 2011-11-04 Impact factor: 10.793
Authors: E Bouzigon; R Nadif; E E Thompson; M P Concas; S Kuldanek; G Du; M Brossard; N Lavielle; C Sarnowski; A Vaysse; P Dessen; R J P van der Valk; L Duijts; A J Henderson; V W V Jaddoe; J C de Jongste; S Casula; G Biino; M-H Dizier; I Pin; R Matran; M Lathrop; M Pirastu; F Demenais; C Ober Journal: Clin Exp Allergy Date: 2015-04 Impact factor: 5.018
Authors: R Lacchini; J J Muniz; Y T D A Nobre; A J Cologna; A C P Martins; J E Tanus-Santos Journal: Pharmacogenomics J Date: 2017-04-04 Impact factor: 3.550
Authors: Sandrah P Eckel; William S Linn; Kiros Berhane; Edward B Rappaport; Muhammad T Salam; Yue Zhang; Frank D Gilliland Journal: PLoS One Date: 2014-01-17 Impact factor: 3.240
Authors: J K Trittmann; L D Nelin; E J Zmuda; J M Gastier-Foster; B Chen; C H Backes; J Frick; P Vaynshtok; V J Vieland; M A Klebanoff Journal: Acta Paediatr Date: 2014-07-06 Impact factor: 2.299